01477.HK
Ocumension Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 5.37
+1.23%Sep 3, 2026, 01:37 UTC
Ocumension Therapeutics announced that the Phase III clinical trial of OT-211 (TRYPTYR acotiamide eye drops) in China has completed enrollment of 398 patients.
Source:Aug 31, 2026, 13:56 UTC
Ocumension Therapeutics announced that the first patient has been enrolled in the Phase III clinical trial of OT-202 for dry eye disease in China.
Source:Jun 18, 2026, 05:49 UTC
Nicox's exclusive licensee Ocumension received positive pre-submission regulatory feedback from the Chinese Center for Drug Evaluation for NCX 470, supporting a planned NDA submission in China.